1. Home
  2. INTS vs TURN Comparison

INTS vs TURN Comparison

Compare INTS & TURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • TURN
  • Stock Information
  • Founded
  • INTS 2012
  • TURN 1981
  • Country
  • INTS United States
  • TURN United States
  • Employees
  • INTS N/A
  • TURN N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • TURN Finance/Investors Services
  • Sector
  • INTS Health Care
  • TURN Finance
  • Exchange
  • INTS Nasdaq
  • TURN Nasdaq
  • Market Cap
  • INTS 33.4M
  • TURN 35.4M
  • IPO Year
  • INTS 2023
  • TURN N/A
  • Fundamental
  • Price
  • INTS $2.35
  • TURN $3.98
  • Analyst Decision
  • INTS Strong Buy
  • TURN
  • Analyst Count
  • INTS 3
  • TURN 0
  • Target Price
  • INTS $8.50
  • TURN N/A
  • AVG Volume (30 Days)
  • INTS 40.1K
  • TURN 45.0K
  • Earning Date
  • INTS 03-13-2025
  • TURN 02-18-2025
  • Dividend Yield
  • INTS N/A
  • TURN N/A
  • EPS Growth
  • INTS N/A
  • TURN N/A
  • EPS
  • INTS N/A
  • TURN N/A
  • Revenue
  • INTS N/A
  • TURN $129,297.00
  • Revenue This Year
  • INTS N/A
  • TURN N/A
  • Revenue Next Year
  • INTS N/A
  • TURN N/A
  • P/E Ratio
  • INTS N/A
  • TURN N/A
  • Revenue Growth
  • INTS N/A
  • TURN 6.32
  • 52 Week Low
  • INTS $1.50
  • TURN $3.12
  • 52 Week High
  • INTS $5.94
  • TURN $4.47
  • Technical
  • Relative Strength Index (RSI)
  • INTS 54.20
  • TURN 55.71
  • Support Level
  • INTS $2.00
  • TURN $3.78
  • Resistance Level
  • INTS $2.37
  • TURN $4.05
  • Average True Range (ATR)
  • INTS 0.31
  • TURN 0.14
  • MACD
  • INTS -0.00
  • TURN -0.01
  • Stochastic Oscillator
  • INTS 48.24
  • TURN 65.20

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

About TURN 180 Degree Capital Corp.

180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.

Share on Social Networks: